6.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Neogenomics Inc Borsa (NEO) Ultime notizie
NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics - Bluefield Daily Telegraph
NeoGenomics Earnings Outlook: Analysts Expect $-0.01 EPS, Guidance Key to Market Reaction - AInvest
AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know - TradingView
NEO Q2 Deep Dive: Guidance Reset Amid Pharma Weakness, Delayed Product Launches - Yahoo Finance
NeoGenomics’s Q2 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
NeoGenomics Misses Q2 Revenue Estimates, Decreases FY Guidance Amid Pharma Services Challenges and Product Launch Delays. - AInvest
Can NeoGenomics Inc. sustain its profitabilityCapital Rotation Trade Suggestions - thegnnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc.NEO - WV News
NeoGenomics Board Member Resigns Amid Valuation Concerns - AInvest
NeoGenomics Board Member Elizabeth Floegel Resigns - TipRanks
Why NeoGenomics Inc. stock attracts strong analyst attentionBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Is NeoGenomics (NEO) a Short-Term Bargain or a High-Risk Speculation? - AInvest
Why NeoGenomics (NEO) Stock Is Trading Up Today - Yahoo Finance
NEOGENOMICS Executives Make Significant Stock Purchases - TradingView
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market - Insider Monkey
What are the latest earnings results for NeoGenomics Inc.Stay informed with expert market forecasts - Jammu Links News
Is NeoGenomics Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What institutional investors are buying NeoGenomics Inc. stockAchieve consistent high returns with low risk - Jammu Links News
Is NeoGenomics Inc. a growth stock or a value stockInvest confidently with data-driven strategies - Jammu Links News
Should I hold or sell NeoGenomics Inc. stock in 2025Fastest-growing stock picks - Jammu Links News
NeoGenomics Inc. Stock Analysis and ForecastBuild wealth steadily with proven stock picks - Jammu Links News
How strong is NeoGenomics Inc. company’s balance sheetAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is NeoGenomics Inc. company’s growth strategyGet timely advice on market trends - Jammu Links News
What makes NeoGenomics Inc. stock price move sharplyDiscover market opportunities with expert help - Jammu Links News
How volatile is NeoGenomics Inc. stock compared to the marketGet timely alerts on market opportunities - Jammu Links News
What drives NeoGenomics Inc. stock priceUnlock daily market insights for better decisions - Jammu Links News
What is the dividend policy of NeoGenomics Inc. stockBreakneck growth rates - Jammu Links News
How many analysts rate NeoGenomics Inc. as a “Buy”Free Popular Stock Recommendations - Jammu Links News
Does NeoGenomics Inc. stock perform well during market downturnsMaximize your returns with smart trade entries - Jammu Links News
What catalysts could drive NeoGenomics Inc. stock higher in 2025High-octane financial growth - Jammu Links News
Is NeoGenomics Inc. stock overvalued or undervaluedExplosive trading opportunities - Jammu Links News
What is the risk reward ratio of investing in NeoGenomics Inc. stockMaximize gains with data-driven stock picks - Jammu Links News
NeoGenomics launches blood-based cancer test for advanced tumors - Gulfshore Business
NeoGenomics Reports Revenue Growth Amid Rising Losses - TipRanks
NeoGenomics Earnings: Analysts Lower Price Target to $8.72 Amid Mixed Opinions on Business Prospects - AInvest
Earnings Release: Here's Why Analysts Cut Their NeoGenomics, Inc. (NASDAQ:NEO) Price Target To US$8.72 - Yahoo Finance
NeoGenomics Earnings Call: Growth Amid Challenges - The Globe and Mail
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript - Insider Monkey
NeoGenomics shares rise 1.37% premarket after launching PanTracer LBx, a blood-based genomic profiling test. - AInvest
NeoGenomics outlines revised 2025 outlook with 9%-10% revenue growth target amid pharma headwinds and PanTracer launch - MSN
Analyzing recovery setups for NeoGenomics Inc. investorsLow Drawdown Real Time Trading Tips Shared - metal.it
A Glimpse Into The Expert Outlook On NeoGenomics Through 3 Analysts - 富途牛牛
NeoGenomics Downgraded to Market Perform by William Blair: Challenges in Oncology Diagnostics - AInvest
NeoGenomics Sees Potential Upside Amidst Challenges and Low Valuation - AInvest
NeoGenomics Experiences Revenue Growth Amid Rising Losses and Impairment Charges. - AInvest
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower - simplywall.st
Momentum Traders Eye NeoGenomics Inc. for Quick BounceVerified Signal From Chart Patterns Detected - beatles.ru
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):